A Dietz1, V Rudat, C Conradt, H Weidauer, A Ho, T Moehler. 1. Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. Andreas_Dietz@med.uni-heidelberg.de
Abstract
BACKGROUND: The objective of this trial was to analyze the prognostic relevance of the angiogenic peptides basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2) in the serum of patients with advanced carcinoma of the head and neck treated by primary radiochemotherapy. METHODS: From 1992 to 1995, 26 patients with advanced head and neck cancer (25 stage IV, 1 stage III UICC) were treated according to the protocol of radiochemotherapy with carboplatin. The pretreatment serum levels VEGF, bFGF, and MMP-2 were measured by ELISA, and data were correlated with tumor characteristics and followed up (median time of follow up, 60 months). RESULTS: An increase in bFGF serum level above the upper limit of normal controls showed a significant correlation with shorter time the of locoregional control (p =.036). In covariant analysis bFGF serum concentration proved to be independent of other prognostic factors like tumor site, age, total tumor volume, and response to therapy. No prognostic relevance of VEGF and MMP-2 serum levels could be determined. CONCLUSIONS: The results of this pilot study indicate that the serum concentration of bFGF has prognostic relevance for advanced head and neck cancer. Copyright 2000 John Wiley & Sons, Inc.
BACKGROUND: The objective of this trial was to analyze the prognostic relevance of the angiogenic peptides basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2) in the serum of patients with advanced carcinoma of the head and neck treated by primary radiochemotherapy. METHODS: From 1992 to 1995, 26 patients with advanced head and neck cancer (25 stage IV, 1 stage III UICC) were treated according to the protocol of radiochemotherapy with carboplatin. The pretreatment serum levels VEGF, bFGF, and MMP-2 were measured by ELISA, and data were correlated with tumor characteristics and followed up (median time of follow up, 60 months). RESULTS: An increase in bFGF serum level above the upper limit of normal controls showed a significant correlation with shorter time the of locoregional control (p =.036). In covariant analysis bFGF serum concentration proved to be independent of other prognostic factors like tumor site, age, total tumor volume, and response to therapy. No prognostic relevance of VEGF and MMP-2 serum levels could be determined. CONCLUSIONS: The results of this pilot study indicate that the serum concentration of bFGF has prognostic relevance for advanced head and neck cancer. Copyright 2000 John Wiley & Sons, Inc.
Authors: Martin Dreilich; Gunnar Wagenius; Stefan Bergström; Daniel Brattström; Anders Larsson; Patrik Hesselius; Michael Bergqvist Journal: Med Oncol Date: 2005 Impact factor: 3.064
Authors: Brendan C Stack; Christopher S Hollenbeak; Christopher M Lee; Frank R Dunphy; Val J Lowe; Paul D Hamilton Journal: World J Surg Oncol Date: 2004-12-14 Impact factor: 2.754
Authors: M Kaya; T Wada; S Kawaguchi; S Nagoya; T Yamashita; Y Abe; H Hiraga; K Isu; M Shindoh; F Higashino; F Okada; M Tada; S Yamawaki; S Ishii Journal: Br J Cancer Date: 2002-03-18 Impact factor: 7.640
Authors: Dirk Rades; Stefan Huttenlocher; Nina D Seibold; Maximilian P Gebhard; Christoph Thorns; Katrin Hasselbacher; Barbara Wollenberg; Steven E Schild Journal: BMC Cancer Date: 2015-03-06 Impact factor: 4.430